Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial - PubMed
4 hours ago
- #Clinical Trial
- #Lithium
- #Mild Cognitive Impairment
- Pilot randomized clinical trial on low-dose lithium for mild cognitive impairment (MCI).
- Examined feasibility, safety, and preliminary efficacy of lithium carbonate in delaying cognitive decline in older adults with MCI.
- No significant differences in the six coprimary outcomes between lithium and placebo groups.
- Lithium group showed slower cognitive decline in CVLT-II scores compared to placebo (0.69 points per year difference).
- No significant treatment effects on hippocampal or cortical gray matter volumes.
- Serious adverse events were similar between groups (29% lithium vs. 23% placebo), none definitely treatment-related.
- Common adverse events included increased creatinine levels, diarrhea, tiredness, and tremor.
- Study concluded feasibility and safety of low-dose lithium in MCI, but no significant clinical benefits were observed.